secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001824293-23-000022
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Vallon receives second Nasdaq delisting notice for equity shortfall; merger with GRI Bio is key to stay
--------------------------------------------------------------------------------

- Stockholders' equity of $2.342M as of Dec 31, 2022, below Nasdaq's $2.5M minimum for continued listing.
- Nasdaq panel granted stay of delisting until April 28, 2023, contingent on completing merger with GRI Bio and meeting initial listing requirements.
- Company previously failed $1.00 minimum bid price rule; hearing held Feb 16, 2023.
- Company expects to close merger by April 28, 2023, but warns no assurance of completion or compliance.
- If merger fails, common stock likely to be delisted from Nasdaq Capital Market.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000022/0001824293-23-000022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429323000022/val-20230228.htm
  HTML page:      https://secwatch.observer/filing/0001824293-23-000022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer